Pfizer (PFE) CEO Albert Bourla criticized FDA vaccine department leadership on Monday, saying the current director ignores staff recommendations amid growing industry-regulator friction. The comments highlight escalating tensions between pharmaceutical companies and health regulators over vaccine policy under the current administration.
Key Takeaways
- Pfizer CEO flags issues with FDA vaccine leadership
- Comments reflect broader industry tensions with health regulators
- Vaccine policy disputes could impact future development investments
Market Context
Pfizer shares traded down 0.72% to $27.45 during Monday’s session 1. The pharmaceutical giant has faced ongoing pressure from changing vaccine policies under Health Secretary Robert F. Kennedy Jr.’s leadership.
The broader pharmaceutical sector has struggled with regulatory uncertainty, as vaccine manufacturers reassess development programs amid shifting federal guidance on mRNA technologies and approval processes.
Leadership Concerns
Speaking at the TD Cowen healthcare conference, Bourla said “I think the current director is not following the recommendations of his staff” when discussing the FDA’s vaccine department 2. The comments represent unusually direct criticism from a major pharmaceutical CEO toward federal regulators.
Bourla has previously characterized discussions with Kennedy’s HHS as productive on topics like cancer and drug pricing. However, he described vaccine conversations as “almost like a religion” and identified “the Secretary of Health” as the main obstacle to productive vaccine policy dialogue 3.
Industry Impact
The regulatory tensions have created investment uncertainty across the vaccine sector. Companies are reportedly winding down development programs and shelving manufacturing plans as the political climate becomes increasingly hostile to vaccine research 4.
Pfizer has defended mRNA technology as “extremely well-tested,” noting the company alone has administered approximately 1.5 billion COVID-19 vaccine doses worldwide 5. The CEO called HHS claims about concealed safety concerns “completely inaccurate.”
Policy Changes
Recent federal policy shifts include terminating Moderna’s $590 million bird flu vaccine contract and changing COVID-19 vaccine recommendations for healthy children and pregnant women. The FDA also announced new clinical trial requirements that could delay future vaccine approvals.
Bourla expressed concerns about whether companies could conduct clinical trials quickly enough to meet new regulatory timelines. He suggested the changes lack scientific justification and fail to follow proper regulatory processes.
Future Outlook
Despite the vaccine policy disputes, Bourla said Pfizer maintains “a very, very close relationship” with the White House on other health priorities. The company continues investing in vaccine research while navigating the challenging regulatory environment.
Industry observers warn that sustained policy uncertainty could undermine U.S. pandemic preparedness and vaccine innovation capabilities. The tensions reflect broader ideological divisions over public health policy that may persist throughout the current administration.
Not investment advice. For informational purposes only.
References
1MarketScreener (March 2, 2026). “Pfizer CEO flags issues with FDA’s vaccine leadership”. Retrieved March 2, 2026.
2Yahoo Finance (March 2, 2026). “Pfizer CEO flags issues with FDA’s vaccine leadership”. Retrieved March 2, 2026.
3BioSpace (January 22, 2026). “‘Almost like a religion’: Pfizer CEO slams RFK Jr.’s ‘anti-science’ vaccine policies”. PharmaLive. Retrieved March 2, 2026.
4Christopher Marquis (March 2, 2026). “Saving Innovation From the Anti-Vaxxers”. Project Syndicate. Retrieved March 2, 2026.
5Meg Tirrell (May 30, 2025). “Pfizer CEO: HHS claims of ‘concealed safety concerns’ on mRNA vaccines are ‘completely inaccurate'”. CNN. Retrieved March 2, 2026.